title: RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes.
abstract: Clinical outcomes for high-risk neuroblastoma patients remains poor, with only 40-50% 5-Year overall survival (OS) and <10% long-term survival. The ongoing acquisition of genetic/molecular rearrangements in undifferentiated neural crest cells may endorse neuroblastoma progression. This study recognized the loss of Retinal Degeneration protein 3, RD3 in aggressive neuroblastoma, and identified its influence in better clinical outcomes and defined its novel metastasis suppressor function. The results showed ubiquitous expression of RD3 in healthy tissues, complete-loss and significant TNM-stage association of RD3 in clinical samples. RD3-loss was intrinsically associated with reduced OS, abridged relapse-free survival, aggressive stage etc., in neuroblastoma patient cohorts. RD3 was transcriptionally and translationally regulated in metastatic site-derived aggressive (MSDAC) cells (regardless of CSC status) ex vivo and in tumor manifolds from metastatic sites in reproducible aggressive disease models in vivo. Re-expressing RD3 in MSDACs reverted their metastatic potential both in vitro and in vivo. Conversely muting RD3 in neuroblastoma cells not only heightened invasion/migration but also dictated aggressive disease with metastasis. These results demonstrate the loss of RD3 in high-risk neuroblastoma, its novel, thus-far unrecognized metastasis suppressor function and further imply that RD3-loss may directly relate to tumor aggressiveness and poor clinical outcomes.
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Faizan H
authors.initials: FH
authors.lastname: Khan
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Vijayabaskar
authors.initials: V
authors.lastname: Pandian
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Satish Kumar
authors.initials: SK
authors.lastname: Ramraj
authors.affiliation: Stephenson Cancer Center, Oklahoma City, OK, USA.
authors.forename: Sheeja
authors.initials: S
authors.lastname: Aravindan
authors.affiliation: Department of Pathology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.
authors.forename: Mohan
authors.initials: M
authors.lastname: Natarajan
authors.affiliation: Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Seifollah
authors.initials: S
authors.lastname: Azadi
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.|Stephenson Cancer Center, Oklahoma City, OK, USA.
authors.forename: Terence S
authors.initials: TS
authors.lastname: Herman
authors.affiliation: Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Natarajan
authors.initials: N
authors.lastname: Aravindan
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D018450:Disease Progression; D005136:Eye Proteins / Q000378:metabolism*; D064593:Heterografts; D006801:Humans; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism* / Q000473:pathology*; D016019:Survival Analysis; D046888:Tissue Array Analysis; D016896:Treatment Outcome
chemical_list: D005136:Eye Proteins; C477438:RD3 protein, human
keywords: RD3; high-risk aggressive neuroblastoma; metastasis; neuroblastoma; tumor suppressor